Perrigo chewses smoking cessation
This article was originally published in The Tan Sheet
Executive Summary
Perrigo receives ANDA generic drug approvals for over-the-counter nicotine polacrilex gum in 2mg and 4 mg doses Sept. 16. The approvals total six, with regular, mint and orange flavors for each dose. The approvals build on the firm's existing smoking cessation portfolio of nicotine replacement patch products (1"The Tan Sheet" Nov. 15, 1999, p. 13)....
You may also be interested in...
Watson Expects To Hold Nicotine Gum Market Position Despite Perrigo Entry
Watson does not expect an ongoing sales lag as a result of Perrigo's recent entry into the generic nicotine gum market
Perrigo Nicotine Patch Introduction Boosts First Quarter Sales Growth
The introduction of Perrigo's private label nicotine transdermal system helped the firm post strong sales and earnings growth for the first quarter ended Oct. 2, the company announced Nov. 9.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.